News Summary:
The AI-based clinical trials solution provider market, encompassing companies like IQVIA developing AI-enabled software platforms and services for clinical trial improvement, is projected for growth through 2034. On September 9, 2026, GENFIT highlighted the long-term commercial opportunity for its MASH diagnostics technology, with IQVIA estimating U.S. peak sales for related products, which focus on blood-based testing to identify patients with at-risk MASH. Earlier, on August 31, 2026, a Q2 earnings roundup evaluated IQVIA's performance among its peers in the drug development inputs and services industry. This followed an August 21, 2026, interview with Mike King, Senior Director of Product & Strategy at IQVIA, who joined in 2022 after two decades in healthcare and life sciences, including leadership positions at Dentsply Sirona and GE Healthcare. Previously, on August 19, 2026, Dr. Padmalakshmi Jnaneshwar, Director of Safety Operations in Lifecycle Safety at IQVIA, shared insights on the evolving field of materiovigilance as medical devices advance, where her teams support medical device pharmacovigilance, drug safety for clinical trials, and post-marketing products.
Subscribe for full access to Iqvia's products in full detail 
